Journal ArticleOPEN ACCESS

Intravenous Cyclophosphamide Pulse Therapy in the Treatment of Systemic Sclerosis-Related Interstitial Lung Disease: A Long Term Study

  • Simeón-Aznar C
  • Fonollosa-Plá V
  • Tolosa-Vilella C
  • et al.
The Open Respiratory Medicine Journal (2008) 02(1) 39-45
DOI: 10.2174/1874306400802010039
N/ACitations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

Interstitial lung disease (ILD) frequently complicates systemic sclerosis (SSc). Cyclophosphamide (CYC) is a promising immunosuppressive therapy for SSc-related ILD. Our objective was to investigate the effectiveness of an intravenous CYC (iv CYC) pulse regime in SSc-related ILD during treatment and thereafter.

Cite

CITATION STYLE

APA

Simeón-Aznar, C. P., Fonollosa-Plá, V., Tolosa-Vilella, C., Selva-O´Callaghan, A., Solans-Laqué, R., Palliza, E., … Vilardell-Tarrés, M. (2008). Intravenous Cyclophosphamide Pulse Therapy in the Treatment of Systemic Sclerosis-Related Interstitial Lung Disease: A Long Term Study. The Open Respiratory Medicine Journal, 02(1), 39–45. https://doi.org/10.2174/1874306400802010039

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free